Balance Sheet

Accounts Payables Accumulated Depreciation Accumulated Expenses Assets Cash & Equivalents Common Equity Construction in Progress Convertible Debt Current Assets Current Deferred Revenue Current Leases Current Taxes Dividends payables Goodwill & Intangibles Intangibles Inventory Land & Improvements Liabilities and Shareholders Equity Long-Term Deferred Tax Long-Term Investments Minority Interest Non-Current Assets Non-Current Debt Notes Payables Operating Leases Other Accumulated Expenses Other Non-Current Assets Other Non-Current Liabilities Payables Preferred Shares Preferred Stock Liabilities Prepaid Assets Property, Plant & Equipment (Net)Raw Materials Receivables Receivables - Accured Receivables - Affiliates Retained Earnings Shareholder's Equity Shares Outstanding Short term Debt Total Current Liabilities Total Debt Total Liabilities Total Non-Current Liabilities Treasury Shares Work In Process

Daily Values

Growth Metrics

Others

Abvc Biopharma (ABVC) Finished Goods (2018 - 2019)

Abvc Biopharma (ABVC) has disclosed Finished Goods for 2 consecutive years, with $94727.0 as the latest value for Q4 2019.

For the quarter ending Q4 2019, Finished Goods fell 5.97% year-over-year to $94727.0, compared with a TTM value of $94727.0 through Dec 2019, down 5.97%, and an annual FY2019 reading of $94727.0, down 5.97% over the prior year.
Finished Goods was $94727.0 for Q4 2019 at Abvc Biopharma, up from $91341.0 in the prior quarter.
Across five years, Finished Goods topped out at $100736.0 in Q4 2018 and bottomed at $91324.0 in Q2 2019.